NICM
ADMA icon

Neo Ivy Capital Management’s ADMA Biologics ADMA Stock Holding History

Neo Ivy Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-199,687
Closed -$1.8M – 350
2026
Q1 		$1.8M Buy
199,687
+130,545
+189% +$2.06M 0.47% 82
2025
Q4 		$1.26M Buy
69,142
+60,302
+682% +$1.02M 0.2% 156
2025
Q3 		$130K Buy
+8,840
New +$152K 0.03% 316
2025
Q2 		– Sell
-20,944
Closed -$416K – 348
2025
Q1 		$416K Sell
20,944
-276,683
-93% -$4.79M 0.13% 203
2024
Q4 		$5.1M Buy
297,627
+249,043
+513% +$4.69M 1.03% 15
2024
Q3 		$972K Buy
+48,584
New +$756K 0.31% 121

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Neo Ivy Capital Management's ADMA Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 199,687 shares — an estimated $1.8M sold.

Neo Ivy Capital Management first reported a position in ADMA in Q3 2024 and held it in 6 quarters. The position peaked at $5.1M in Q4 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 199,687 ADMA Biologics shares in Q2 2026, an estimated $1.8M.
  • Neo Ivy Capital Management first reported a position in ADMA Biologics in Q3 2024 and held it in 6 quarters.
  • Neo Ivy Capital Management's ADMA Biologics position peaked at $5.1M in Q4 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.